Early next year, dermatologists could have a new weapon with which to do battle against acne.<br />According to Allure, the topical cream Winlevi was officially approved at the end of August by the United States Food and Drug Administration.<br />Winlevi, also called Clascoterone Cream 1%, is the only topical medication that targets the androgen receptors in the skin.<br />Androgens are hormones that are responsible for driving sebum production and inflammation. The result is less sebum production and oil buildup.<br />Winlevi's manufacturer says the drug's active ingredient, clascoterone, 'acts by limiting the effects of these hormones,' leading to fewer breakouts.
